Jasper Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
JSPR$16.37-2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit Number | Description | Registrant’s Form | Date Filed with the SEC | Exhibit Number |
|---|---|---|---|---|
| 3.1 | Second Amended and Restated Certificate of Incorporation of the Registrant, dated September 24, 2021. | 8-K | 9/29/2021 | 3.1 |
| 3.2 | Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation, dated June 8, 2023. | 8-K | 6/8/2023 | 3.1 |
| 3.3 | Certificate of Second Amendment to the Second Amended and Restated Certificate of Incorporation of Jasper Therapeutics, Inc. January 3, 2024. | 8-K | 1/3/2024 | 3.1 |
| 3.4 | Third Amended and Restated Bylaws of the Registrant. | 8-K | 2/17/2023 | 3.1 |
| 4.1 | Form of Warrant Agreement, dated November 19, 2019, by and between the Registrant and Continental Stock Transfer & Trust Company, as warrant agent. | 8-K | 11/25/2019 | 4.1 |
| 4.2 | Specimen Warrant Certificate. | S-1/A | 11/6/2019 | 4.3 |
| 4.3 | Form of Pre-Funded Warrant to Purchase Common Stock. | 8-K | 9/19/2025 | 4.1 |
| 4.4 | Form of Common Warrant. | 8-K | 9/19/2025 | 4.2 |
| 31.1* | Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934. | |||
| 31.2* | Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934. | |||
| 32.1** | Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||
| 101.INS* | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |||
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document. | |||
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |||
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |||
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document. | |||
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |||
| 104* | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). | |||
| * | Filed herewith. |
|---|
| ** | Furnished herewith. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.